Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥18 to ≤75 years old
Male or female participants
Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information
Men able to father a child must be willing to use male contraception (condom or sexual abstinence) consistently and correctly until end of study. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information
Signed and dated written informed consent in accordance with ICH-Good Clinical Practice (GCP) and local legislation prior to admission to the trial
Patients meeting criteria for Child-Pugh category A
Adequate organ function or liver laboratory tests defined as all of the following:
* Total bilirubin ≤1.5 mg/dL. If the total bilirubin is \> upper limit of normal (ULN) and a ≤1.5 mg/dL, the direct bilirubin must be \<50% of total bilirubin
* For patients with Gilbert's syndrome: total bilirubin ≤3x ULN or direct bilirubin ≤1.5x ULN
* Aspartate transaminase (AST) and alanine transaminase (ALT) ≤5x ULN
* Alkaline Phosphatase \<1.5x ULN
* International Normalized Ratio (INR) ≤1.4
* Model for End-Stage Liver Disease (MELD) score \<12
* Platelet count ≥110 000/mL
* Albumin \>3.4 g/dl
You may not be if
Major surgery (major according to the investigator's assessment) performed within 24-weeks prior to randomization, major surgery planned within 6 months after screening (e.g. hip replacement), or bariatric surgery within 2 years prior to randomization
Any documented active or suspected malignancy or history of malignancy within 5-years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix. Specifically, any patients with suspected, confirmed, or history of hepatocellular carcinoma will be excluded
Suspected or confirmed portal vein thrombosis within 6 months of enrollment
History of liver transplantation
Current listing for liver transplantation
Present or past evidence of hepatic decompensation, in the opinion of the investigator, including but not limited to variceal hemorrhage, ascites, and/or hepatic encephalopathy
Patients with clinically significant portal hypertension defined by any one of the following:
* FibroScan ≥25 Kilo Pascal (kPA) if the platelets are ≥150,000/μL
* FibroScan ≥20 kPA if platelets are \<150,000/μL
* Evidence of esophageal or gastric varices (≥grade1) on the most recent endoscopy
* Enhanced liver fibrosis (ELF) ≥11.3
* Hepatic venous pressure gradient (HVPG) ≥10 mm Hg
Clareo Health | A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
